Drug Type Small molecule drug |
Synonyms RP-0217 |
Target |
Action inhibitors |
Mechanism PP2A inhibitors(Protein phosphatase 2A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Preclinical | United Kingdom | 01 Jan 2024 | |
Colitis, Ulcerative | Preclinical | United Kingdom | 01 Jan 2024 | |
Crohn Disease | Preclinical | United Kingdom | 01 Jan 2024 | |
Inflammation | Preclinical | United Kingdom | 01 Jan 2024 | |
Pulmonary Disease, Chronic Obstructive | Preclinical | United Kingdom | 01 Jan 2024 | |
Rhinitis | Preclinical | United Kingdom | 01 Jan 2024 |